|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
|
Managing Patients with Rheumatic Disorders in Primary Care
Rheumatic disorders are prevalent, yet their diagnosis and treatment in affected patients are frequently challenging, contributing to a considerable disease burden. Ensuring timely intervention is critical to slow disease progression and improve patient outcomes. However, various educational gaps impede primary care clinicians from effectively achieving these goals. This 0.75-hour text-based activity features 3 modules comprised of 12 questions encountered in the primary care management of pat... |
|
|
How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment r... |
|
|
Answers to the Questions You May Not be Asking: Treating Ulcerative Colitis Considerate of Patient-Centric Factors
Are you aware of the latest evidence-based strategies in ulcerative colitis (UC)? Looking to expand your ability to incorporate patient-centric factors into selection of therapy for UC? Navigate through this novel, interactive self-directed activity designed to optimize your decision making in selection of therapy for UC. View expert perspectives and insights who can help you apply newer strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment for your ... |
|
|
Prurigo Nodularis: Recognizing, Diagnosing and Treating a Rare but Debilitating Disease
Prurigo Nodularis is a rare, chronic skin disorder that causes substantial patient burden, but is often overlooked or misdiagnosed and, until recently, had no medications approved by the US Food and Drug Administration. The interprofessional faculty share their real-world perspectives on the diagnosis and treatment of patients with prurigo nodularis to reduce patient burden of disease and improve health outcomes. Highlighting pathophysiologic mechanisms, the faculty discuss the evolving pharma... |
|
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |
|
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|
|
Therapy Tidbits Summer 2021
Therapy Tidbits – Summer 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
• Improving Health through Community Policies Gains Momentum – Provides an overview of the Blue Zone Project and the impact on community members’ health.
• Psychologis... |
|
|
Therapy Tidbits Spring 2022
Therapy Tidbits – Spring 2022 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2022 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are:
No Surprises Act (NSA) Clarifies Patient Rights – Discusses the NSA and provides guidance in demonstrating good faith attempts at compliance.
Pharmacists Can be Valuable A... |
|